Treatment of high-grade gliomas continues to be frustrating for the clinician as the medial survival stands at a dismal 14.5 months for glioblastoma multiforme (GBM) with the current standard of care. Given the high dose and generous margins required to be irradiated, three dimensional conformal radiotherapy (3DCRT) has become standard practice. Radiation dose escalation beyond 60 Gy, by means of stereotactic or intensity modulated radiotherapy (IMRT) boost, has not yielded clinically significant benefits in terms of local control or survival. At the same time, the potential of IMRT to spare normal tissues such as the brain stem and the optic apparatus makes it an attractive tool for modern radiation oncologists in seeking to improve post-radiotherapy quality of life. At our centre, we have been treating a large number of cases of high grade glioma with 3DCRT and IMRT for the last several years. The present study has been an effort to understand any potential benefits that IMRT, even without dose escalation, can offer.
Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolamide in glioblastoma. N Eng J Med (2005); 352;10: 987-996.
Shaw EG, Steiber V, Tatter S, et al. A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM)[abstract]. Int J Radiat Oncol Biol Phys (2002); 54:206.
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.